EUVIMEDEUVIMED entdecken
Crossref

Comparative Efficacy and Safety of Four Novel Monoclonal Antibody PCSK9 Inhibitors: A Bayesian Network Meta‐Analysis of Lipid and Safety Outcomes

Kainat Warraich iD, Muhammad Mujtaba Rasool iD, Muhammad Farhan iD, Muhammad Murtaza iD, Luis Alejandro Morales Ojeda iD, Farah Khan, Hammad Amjad iD, Muddassir Syed Saleem, Sheikh Muhammad Ebtehaj Ali iD, Ashish Sarraju iD

Journal of the American Heart Association · 10.11.2026

DOI: 10.1161/jaha.126.055325 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, online erschienen am 10.11.2026. Verfasst von Kainat Warraich und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Cleveland OH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Four novel monoclonal antibody proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors—tafolecimab, ongericimab, ebronucimab, and recaticimab—lower low‐density lipoprotein cholesterol (LDL‐C) in placebo‐controlled trials but have never been compared head to head.

Methods

We searched PubMed, Embase, Scopus, CENTRAL, and ClinicalTrials.gov from inception to 8 June 2026 and performed a Bayesian random‐effects network meta‐analysis of randomized placebo‐controlled trials across eight lipid outcomes, analyzed by dose–interval regimen, and adverse events, analyzed by drug (PROSPERO CRD420261422519). Risk of bias was assessed with RoB 2 and certainty of evidence with CINeMA. Lipid effects are placebo‐adjusted differences in percentage change from baseline with 95% credible intervals (CrIs).

Results

Thirteen trials were included. In the LDL‐C network (4,517 patients; 16 regimens), every regimen lowered LDL‐C (−45.2% to −80.2%), with concordant reductions in non–high‐density lipoprotein cholesterol, apolipoprotein B, and total cholesterol. Most between‐agent differences were small, but some indirect contrasts had CrIs excluding zero; most consistently, ongericimab 150 mg every 2 weeks lowered LDL‐C more than the three phase 3 recaticimab regimens (differences −14.4% to −18.6%), robust to adjustment for background statin therapy and baseline LDL‐C. Rank intervals were wide. The largest triglyceride and high‐density lipoprotein cholesterol effects of recaticimab were confined to small phase 1b/2 regimens. No agent differed from placebo for any adverse event or serious adverse events, although information was limited; injection‐site reactions were more frequent with active treatment. Certainty of evidence was moderate to very low versus placebo and very low between agents.

Conclusions

All four antibodies produced substantial reductions in atherogenic lipids without a detected safety signal beyond injection‐site reactions. Indirect between‐agent differences are hypothesis‐generating and do not establish a hierarchy; head‐to‐head and cardiovascular outcome trials are needed.

Schlagwörter

Stichwörter der Autor:innen

LDL cholesterolPCSK9 inhibitorshypercholesterolemiamonoclonal antibodiesnetwork meta‐analysis

Autor:innen und Institutionen

  • Cleveland Clinic Cleveland OH.
  • Allama Iqbal Medical College Lahore Pakistan.
  • Karachi Medical and Dental College Karachi Pakistan.
  • Services Institute of Medical Sciences Lahore Pakistan.
  • University of Colorado Anschutz Aurora CO.
  • Allama Iqbal Medical College/Jinnah Hospital Lahore Pakistan.

ORCID-Profile: Kainat Warraich, Muhammad Mujtaba Rasool, Muhammad Farhan, Muhammad Murtaza, Luis Alejandro Morales Ojeda, Hammad Amjad, Sheikh Muhammad Ebtehaj Ali, Ashish Sarraju

Zitieren

APA

Warraich, K., Rasool, M. M., Farhan, M., Murtaza, M., Morales Ojeda, L. A., Khan, F., Amjad, H., Saleem, M. S., Ali, S. M. E., & Sarraju, A. (2026). Comparative Efficacy and Safety of Four Novel Monoclonal Antibody PCSK9 Inhibitors: A Bayesian Network Meta‐Analysis of Lipid and Safety Outcomes. Journal of the American Heart Association. https://doi.org/10.1161/jaha.126.055325

Vancouver

Warraich K, Rasool MM, Farhan M, Murtaza M, Morales Ojeda LA, Khan F, et al. Comparative Efficacy and Safety of Four Novel Monoclonal Antibody PCSK9 Inhibitors: A Bayesian Network Meta‐Analysis of Lipid and Safety Outcomes. Journal of the American Heart Association. 2026. doi:10.1161/jaha.126.055325

BibTeX
@article{Warraich2026,
  author = {Warraich, Kainat and Rasool, Muhammad Mujtaba and Farhan, Muhammad and Murtaza, Muhammad and Morales Ojeda, Luis Alejandro and Khan, Farah and Amjad, Hammad and Saleem, Muddassir Syed and Ali, Sheikh Muhammad Ebtehaj and Sarraju, Ashish},
  title = {Comparative Efficacy and Safety of Four Novel Monoclonal Antibody PCSK9 Inhibitors: A Bayesian Network Meta‐Analysis of Lipid and Safety Outcomes},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.126.055325}
}
Kostenlos starten →